Clinical Trial

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2018-04-26; most recent amendment 2026-03-13.
Status change: Recruiting → Active, Not Recruiting 2019-10-13
Trial Details
NCT Number NCT03519230
Lead Sponsor BeiGene
Conditions Ovarian Cancer
Enrollment 224 participants
Start Date 2018-05-14
Primary Completion 2025-12-01 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-16